1
|
Vayne C, Rollin J, Clare R, Daka M, Atsouawe M, Guéry EA, Cauchie P, Cordonnier C, Cuisenier P, De Maistre E, Donnard M, Drillaud N, Faille D, Galinat H, Gouin-Thibault I, Lemoine S, Mourey G, Mullier F, Siguret V, Susen S, Godon A, Nazy I, Gruel Y, Pouplard C. THE USE OF 1E12, A MONOCLONAL ANTI-PLATELET FACTOR 4 ANTIBODY TO IMPROVE THE DIAGNOSIS OF VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA. J Thromb Haemost 2024:S1538-7836(24)00287-3. [PMID: 38762021 DOI: 10.1016/j.jtha.2024.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 04/04/2024] [Accepted: 05/02/2024] [Indexed: 05/20/2024]
Abstract
BACKGROUND Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a complication of adenoviral-based vaccine against SARS-COV-2 due to prothrombotic IgG antibodies to platelet factor 4 (PF4), and may be difficult to distinguish from heparin-induced thrombocytopenia (HIT) in patients treated with heparin. OBJECTIVES We assessed the usefulness of competitive anti-PF4 enzyme immunoassays (EIA) in this context. METHODS The ability of F(ab')2 fragments of 1E12, 1C12 and 2E1, 3 monoclonal anti-PF4 antibodies, to inhibit the binding of human VITT or HIT antibodies to PF4 was evaluated using EIAs. Alanine scanning mutagenesis was performed to define the amino acids (AA) involved in the interactions between the monoclonal antibodies and PF4. RESULTS A strong inhibition of VITT IgG binding to PF4 was measured with 1E12 (median inhibition 93%, n=8), whereas it had no effect on the binding of HIT antibodies (median: 6%, n=8). In contrast, 1C12 and 2E1 inhibited VITT (median: 74 and 76%, respectively) and HIT antibodies (median: 68 and 53%, respectively) binding to PF4. When a competitive anti-PF4 EIA was performed with 1E12 for 19 additional VITT samples, it strongly inhibited IgG binding to PF4, except for one patient, who had actually developed HIT according to the clinical history. Epitope mapping showed that 1E12 interacts with 5 key AAs on PF4, of which 4 are also required for the binding of human VITT antibodies, thus explaining the competitive inhibition. CONCLUSIONS A simple competitive anti-PF4 EIA with 1E12 could help confirm VITT diagnosis and distinguish it from HIT in patients when both diagnoses are possible.
Collapse
Affiliation(s)
- Caroline Vayne
- Regional University Hospital Centre Tours, Department of Haemostasis, Tours, France; University of Tours, EA4245 Transplantation, Immunologie, Inflammation, Tours, France.
| | - Jérôme Rollin
- Regional University Hospital Centre Tours, Department of Haemostasis, Tours, France; University of Tours, EA4245 Transplantation, Immunologie, Inflammation, Tours, France
| | - Rumi Clare
- McMaster University, Department of Medicine, Hamilton, Ontario, Canada; Michael G DeGroote Centre for Transfusion Research, Hamilton, Ontario, Canada
| | - Mercy Daka
- McMaster University, Department of Medicine, Hamilton, Ontario, Canada; Michael G DeGroote Centre for Transfusion Research, Hamilton, Ontario, Canada
| | - Merveille Atsouawe
- University of Tours, EA4245 Transplantation, Immunologie, Inflammation, Tours, France
| | - Eve-Anne Guéry
- Regional University Hospital Centre Tours, Department of Haemostasis, Tours, France
| | - Philippe Cauchie
- CHU de Charleroi, Service de Biologie Clinique, Charleroi, Belgique
| | - Charlotte Cordonnier
- Univ. Lille, Inserm, CHU Lille, U1172-LilNCog - Lille Neuroscience & Cognition, Lille, France
| | - Pauline Cuisenier
- University Hospital of Grenoble Alpes, Stroke Unit, Neurology departement, Grenoble, France
| | | | - Magali Donnard
- Limoges University Hospital, Haemostasis unit, Limoges, France
| | - Nicolas Drillaud
- Nantes University Hospital, Department of Haemostasis, Nantes, France
| | - Dorothée Faille
- CHU Bichat-Claude Bernard, Département d'Hématologie Biologique, INSERM U1148, Laboratory for Vascular Translational Science, Paris, France
| | - Hubert Galinat
- CHRU Brest, Service d'Hématologie Biologique, Brest, France
| | - Isabelle Gouin-Thibault
- University Hospital of Rennes, Department of hemostasis, INSERM, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR_S 1085, University of Rennes, 35000, Rennes, France
| | - Sandrine Lemoine
- Université d'Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Laboratoire d'Hématologie, F-49000, Angers, France
| | - Guillaume Mourey
- Établissement Français du Sang Bourgogne -Franche-Comté, Laboratoire d'Hématologie et d'Immunologie Régional, Besançon, France
| | - François Mullier
- Université catholique de Louvain, CHU UCL NAMUR, Namur Thrombosis and Hemostasis Center (NTHC), Yvoir, Belgium
| | - Virginie Siguret
- Hôpital Lariboisière, Service d'Hématologie biologique, University of Paris, INSERM UMR_S1140, Innovative therapeutics in Haemostasis, Paris, France
| | - Sophie Susen
- Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France
| | - Alban Godon
- Université d'Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, Laboratoire d'Hématologie, F-49000, Angers, France
| | - Ishac Nazy
- McMaster University, Department of Medicine, Hamilton, Ontario, Canada; Michael G DeGroote Centre for Transfusion Research, Hamilton, Ontario, Canada; McMaster University, Department of Biochemistry and Biomedical Sciences, Hamilton, Ontario, Canada
| | - Yves Gruel
- Regional University Hospital Centre Tours, Department of Haemostasis, Tours, France; University of Tours, EA4245 Transplantation, Immunologie, Inflammation, Tours, France
| | - Claire Pouplard
- Regional University Hospital Centre Tours, Department of Haemostasis, Tours, France; University of Tours, EA4245 Transplantation, Immunologie, Inflammation, Tours, France
| |
Collapse
|
2
|
Foret T, Dufrost V, Lagrange J, Costa P, Mourey G, Lecompte T, Magy-Bertrand N, Regnault V, Zuily S, Wahl D. Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives. Curr Rheumatol Rep 2024; 26:178-187. [PMID: 38372872 DOI: 10.1007/s11926-024-01140-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/05/2024] [Indexed: 02/20/2024]
Abstract
PURPOSE OF THE REVIEW Thrombotic risk assessment in antiphospholipid positive (aPL +) subjects is a major challenge, and the study of in vitro thrombin generation (thrombin generation assays (TGA)) could provide useful information. Activated protein C (APC) sensitivity is involved in thrombotic events in antiphospholipid syndrome patients. We summarized methods used to assess APC sensitivity with TGA and evaluated the prognostic role of APC resistance through literature search. RECENT FINDINGS APC resistance induced by aPL is a complex pathway. Several cross-sectional studies assessed APC sensitivity to understand thrombotic event mechanisms in aPL + subjects. Only one prospective cohort had investigated the prognostic impact of APC resistance in aPL + subjects, with a positive and significant correlation between APC sensitivity and the risk of thrombosis during the follow up (hazard ratio, 6.07 [95% CI, 1.69-21.87]). APC resistance assessed with TGA could be associated with thrombotic events in aPL + subjects.
Collapse
Affiliation(s)
- Thomas Foret
- Vascular Medicine Unit, Vascular and Endovascular Surgery Department, CHU-Besancon, 3 BD Alexandre Fleming, F-25000, Besancon, France.
- Université de Franche-Comté, SINERGIES, F-25000, Besancon, France.
| | - Virginie Dufrost
- Université de Lorraine, INSERM, DCAC, F-54000, Nancy, France
- Vascular Medicine Division and National Referral Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU-Nancy, F-54000, Nancy, France
| | - Jeremy Lagrange
- Université de Lorraine, INSERM, DCAC, F-54000, Nancy, France
- CHRU-Nancy, F-54000, Nancy, France
| | - Patricia Costa
- Vascular Medicine Unit, Vascular and Endovascular Surgery Department, CHU-Besancon, 3 BD Alexandre Fleming, F-25000, Besancon, France
| | - Guillaume Mourey
- Université de Franche-Comté, SINERGIES, F-25000, Besancon, France
- Medical Biology Laboratory, Biological Haemostasis Department, CHU Besançon, F-25000, Besançon, France
| | - Thomas Lecompte
- Vascular Medicine Division and National Referral Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU-Nancy, F-54000, Nancy, France
- Université de Lorraine, Nancy, France
| | | | - Veronique Regnault
- Université de Lorraine, INSERM, DCAC, F-54000, Nancy, France
- CHRU-Nancy, F-54000, Nancy, France
| | - Stéphane Zuily
- Université de Lorraine, INSERM, DCAC, F-54000, Nancy, France
- Vascular Medicine Division and National Referral Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU-Nancy, F-54000, Nancy, France
| | - Denis Wahl
- Université de Lorraine, INSERM, DCAC, F-54000, Nancy, France
- Vascular Medicine Division and National Referral Center for Rare Vascular and Systemic Autoimmune Diseases, CHRU-Nancy, F-54000, Nancy, France
| |
Collapse
|
3
|
Billoir P, Siguret V, Fron EM, Drouet L, Crassard I, Marlu R, Barbieux-Guillot M, Morange PE, Robinet E, Metzger C, Wolff V, André-Kerneis E, Klapczynski F, Martin-Bastenaire B, Pico F, Menard F, Ellie E, Freyburger G, Rouanet F, Allano HA, Godenèche G, Mourey G, Moulin T, Berruyer M, Derex L, Trichet C, Runavot G, Le Querrec A, Viader F, Cluet-Dennetiere S, Husein TT, Donnard M, Macian-Montoro F, Ternisien C, Guillon B, Laplanche S, Zuber M, Peltier JY, Tassan P, Roussel B, Canaple S, Scavazza E, Gaillard N, Bagan AT, Le Cam Duchez V. C-reactive protein and D-dimer in Cerebral Vein Thrombosis: relation to clinical, imaging characteristics and outcomes in a French cohort study. Res Pract Thromb Haemost 2023; 7:100130. [PMID: 37138790 PMCID: PMC10149398 DOI: 10.1016/j.rpth.2023.100130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 03/03/2023] [Accepted: 03/08/2023] [Indexed: 03/30/2023] Open
Abstract
Introduction Cerebral venous sinus thrombosis (CVST) is a rare disease with highly variable clinical presentation and outcomes. Clinical studies suggest a role of inflammation and coagulation in CVST outcomes. The aim of this study was to investigate the association of inflammation and hypercoagulability biomarkers with CVST clinical manifestations and prognosis. Methods This prospective multicenter study was conducted from July 2011 to September 2016. Consecutive patients referred to 21 French stroke units and who had a diagnosis of symptomatic CVST were included. High-sensitivity C-reactive protein (hs-CRP), neutrophil-to-lymphocyte ratio (NLR), D-dimer, and thrombin generation using calibrated automated thrombogram system were measured at different time points until 1 month after anticoagulant therapy discontinuation. Results Two hundred thirty-one patients were included. Eight patients died, of whom 5 during hospitalization. The day 0 hs-CRP levels, NLR, and D-dimer were higher in patients with initial consciousness disturbance than in those without (hs-CRP: 10.2 mg/L [3.6-25.5] vs 23.7 mg/L [4.8-60.0], respectively; NLR: 3.51 [2.15-5.88] vs 4.78 [3.10-9.59], respectively; D-dimer: 950 μg/L [520-2075] vs 1220 μg/L [950-2445], respectively). Patients with ischemic parenchymal lesions (n = 31) had a higher endogenous thrombin potential5pM than those with hemorrhagic parenchymal lesions (n = 31): 2025 nM min (1646-2441) vs 1629 nM min (1371-2090), respectively (P = .0082). Using unadjusted logistic regression with values >75th percentile, day 0 hs-CRP levels of >29.7 mg/L (odds ratio, 10.76 [1.55-140.4]; P = .037) and day 5 D-dimer levels of >1060 mg/L (odds ratio, 14.63 [2.28-179.9]; P = .010) were associated with death occurrence. Conclusion Two widely available biomarkers measured upon admission, especially hs-CRP, could help predict bad prognosis in CVST in addition to patient characteristics. These results need to be validated in other cohorts.
Collapse
|
4
|
Besch G, Ilic D, Ginet M, d’Audigier C, Nguyen P, Ferreira D, Samain E, Mourey G, Pili-Floury S. Identification of Heparin-Induced Thrombocytopenia in Surgical Critically Ill Patients by Using the HIT Expert Probability Score: An Observational Pilot Study. J Clin Med 2022; 11:jcm11061515. [PMID: 35329842 PMCID: PMC8951334 DOI: 10.3390/jcm11061515] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 03/03/2022] [Accepted: 03/06/2022] [Indexed: 12/03/2022] Open
Abstract
Background: Heparin-induced thrombocytopenia (HIT) remains a challenging diagnosis especially in surgical intensive care unit (SICU) patients. The aim of the study was to evaluate for the first time the diagnostic accuracy of the HIT Expert Probability (HEP) score in the early identification of HIT in SICU patients. Methods: The HEP and 4Ts scores were calculated in all patients with suspected HIT during their stay in our SICU. The diagnosis of HIT was finally confirmed (HIT+ group) or excluded (HIT− group) by an independent committee blinded to the HEP and 4Ts score values. The primary outcome was the sensitivity and specificity of a HEP score ≥ 5 for the diagnosis of HIT. The secondary outcome was the area under the ROC curve (AUC) of the HEP and 4Ts scores in the diagnosis of HIT. Results: Respectively 6 and 113 patients were included in the HIT+ and HIT− groups. A HEP score value ≥ 5 had a sensitivity (95% confidence interval (95% CI)) of 1.00 (0.55−1.00), and a specificity (95% CI) of 0.92 (0.86−0.96). The AUC (95% CI) was significantly higher for the HEP score versus for the 4Ts score (0.967 (0.922−1.000) versus 0.707 (0.449−0.965); p = 0.035). Conclusions: A HEP score value < 5 could be helpful to rule out HIT in SICU patients.
Collapse
Affiliation(s)
- Guillaume Besch
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, F-25000 Besancon, France; (D.I.); (M.G.); (D.F.); (E.S.); (S.P.-F.)
- EA3920, University of Franche-Comte, 3 bvd Alexander Fleming, F-25000 Besancon, France
- Correspondence:
| | - Dejan Ilic
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, F-25000 Besancon, France; (D.I.); (M.G.); (D.F.); (E.S.); (S.P.-F.)
| | - Marc Ginet
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, F-25000 Besancon, France; (D.I.); (M.G.); (D.F.); (E.S.); (S.P.-F.)
| | - Clément d’Audigier
- Etablissement Français du Sang Bourgogne Franche-Comté, Hemostasis Department, Laboratoire de Biologie Médicale et de Greffe, F-25000 Besançon, France; (C.d.); (G.M.)
| | - Philippe Nguyen
- Department of Haematology, CHU Robert Debré, F-51000 Reims, France;
- EA3801, IFR-53, Reims Champagne-Ardenne University, F-51000 Reims, France
| | - David Ferreira
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, F-25000 Besancon, France; (D.I.); (M.G.); (D.F.); (E.S.); (S.P.-F.)
- EA481, Integrative and Clinical Neuroscience Laboratory, University Hospital of Besancon, F-25000 Besancon, France
| | - Emmanuel Samain
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, F-25000 Besancon, France; (D.I.); (M.G.); (D.F.); (E.S.); (S.P.-F.)
- EA3920, University of Franche-Comte, 3 bvd Alexander Fleming, F-25000 Besancon, France
| | - Guillaume Mourey
- Etablissement Français du Sang Bourgogne Franche-Comté, Hemostasis Department, Laboratoire de Biologie Médicale et de Greffe, F-25000 Besançon, France; (C.d.); (G.M.)
- Department of Clinical Hemostasis, University Hospital of Besancon, F-25000 Besancon, France
| | - Sebastien Pili-Floury
- Department of Anesthesiology and Intensive Care Medicine, University Hospital of Besancon, F-25000 Besancon, France; (D.I.); (M.G.); (D.F.); (E.S.); (S.P.-F.)
- EA3920, University of Franche-Comte, 3 bvd Alexander Fleming, F-25000 Besancon, France
| |
Collapse
|
5
|
Triquenot Bagan A, Crassard I, Drouet L, Barbieux-Guillot M, Marlu R, Robinet-Borgomino E, Morange PE, Wolff V, Grunebaum L, Klapczynski F, André-Kerneis E, Pico F, Martin-Bastenaire B, Ellie E, Menard F, Rouanet F, Freyburger G, Godenèche G, Allano HA, Moulin T, Mourey G, Derex L, Berruyer M, Runavot G, Trichet C, Viader F, Le Querrec A, Husein TT, Cluet-Dennetiere S, Macian-Montoro F, Donnard M, Guillon B, Ternisien C, Zuber M, Laplanche S, Tassan P, Peeltier JY, Canaple S, Roussel B, Gaillard N, Scavazza E, Le Cam Duchez V. Cerebral Venous Thrombosis: Clinical, Radiological, Biological, and Etiological Characteristics of a French Prospective Cohort (FPCCVT)-Comparison With ISCVT Cohort. Front Neurol 2021; 12:753110. [PMID: 34819911 PMCID: PMC8606816 DOI: 10.3389/fneur.2021.753110] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 09/30/2021] [Indexed: 11/28/2022] Open
Abstract
Introduction: Cerebral venous thrombosis (CVT) is a rare disease with highly variable clinical presentation and outcome. Etiological assessment may be negative. The clinical and radiological presentation and evolution can be highly variable. The mechanisms involved in this variability remain unknown. Objective: The aim of this multicenter French study registered on ClinicalTrials.gov (NCT02013635) was therefore to prospectively recruit a cohort of patients with cerebral venous thrombosis (FPCCVT) in order to study thrombin generation and clot degradation, and to evaluate their influence on clinical radiological characteristics. The first part of the study was to compare our cohort with a reference cohort. Methods: This prospective, multicenter, French study was conducted from July 2011 to September 2016. Consecutive patients (aged >15 years) referred to the stroke units of 21 French centers and who had a diagnosis of symptomatic CVT were included. All patients gave their written informed consent. The diagnosis of CVT had to be confirmed by imaging. Clinical, radiological, biological, and etiological characteristics were recorded at baseline, at acute phase, at 3 months and at last follow-up visit. Thrombophilia screening and the choice of treatment were performed by the attending physician. All data were compared with data from the International Study on CVT published by Ferro et al. Results: Two hundred thirty-one patients were included: 117 (50.6%) had isolated intracranial hypertension, 96 (41.5%) had focal syndrome. During hospitalization, 229 (99.1%) patients received anticoagulant treatment. Median length of hospital stay was 10 days. Five patients died during hospitalization (2.2%). At 3 months, 216 patients (97.0%) had follow-up with neurological data based on an outpatient visit. The mean duration of antithrombotic treatment was 9 months, and the mean time to last follow-up was 10.5 months. At the end of follow-up, eight patients had died, and 26 patients were lost to follow-up. At least one risk factor was identified in 200 patients. Conclusions: We demonstrated that the FPCCVT cohort had radiological, biological, and etiological characteristics similar to the historical ISCVT cohort. Nevertheless, the initial clinical presentation was less severe in our study probably due to an improvement in diagnostic methods between the two studies.
Collapse
Affiliation(s)
| | - Isabelle Crassard
- Department of Neurology, Lariboisière University Hospital, Paris, France
| | - Ludovic Drouet
- Department of Biological Hematology, Lariboisière University Hospital, Paris, France
| | | | - Raphaël Marlu
- Department of Biological Hematology, Grenoble University Hospital, Grenoble, France
| | | | | | - Valérie Wolff
- Stroke Unit, Strasbourg University Hospital, Strasbourg, France
| | - Lelia Grunebaum
- Department of Biological Hematology, Strasbourg University Hospital, Strasbourg, France
| | | | | | - Fernando Pico
- Department of Neurology Versailles Hospital, Versailles, France
| | | | - Emmanuel Ellie
- Department of Neurology, Bayonne Hospital, Bayonne, France
| | - Fanny Menard
- Department of Biological Hematology, Bayonne Hospital, Bayonne, France
| | - François Rouanet
- Department of Neurology, Bordeaux University Hospital, Bordeaux, France
| | - Geneviève Freyburger
- Department of Biological Hematology, Etablissement Français du Sang, Bordeaux, France
| | - Gaëlle Godenèche
- Department of Neurology, La Rochelle Hospital, La Rochelle, France
| | - Hong-An Allano
- Department of Biological Hematology, La Rochelle Hospital, La Rochelle, France
| | - Thierry Moulin
- Department of Neurology, Besançon University Hospital, Besançon, France
| | - Guillaume Mourey
- Department of Biological Hematology, Etablissement Français du Sang, Besançon, France
| | - Laurent Derex
- Department of Neurology, Lyon University Hospital, Lyon, France
| | - Micheline Berruyer
- Department of Biological Hematology, Lyon University Hospital, Lyon, France
| | | | - Catherine Trichet
- Department of Biological Hematology, Argenteuil Hospital, Argenteuil, France
| | - Fausto Viader
- Department of Neurology, Caen University Hospital, Caen, France
| | - Agnès Le Querrec
- Department of Biological Hematology, Caen University Hospital, Caen, France
| | | | | | | | - Magali Donnard
- Department of Biological Hematology, Limoges University Hospital, Limoges, France
| | - Benoît Guillon
- Department of Neurology, Nantes University Hospital, Nantes, France
| | - Catherine Ternisien
- Department of Biological Hematology, Nantes Univeristy Hospital, Nantes, France
| | - Mathieu Zuber
- Department of Neurology, Saint Joseph Hospital, Paris, France
| | - Sophie Laplanche
- Department of Biological Hematology, Saint Joseph Hospital, Paris, France
| | - Philippe Tassan
- Department of Neurology, Poissy-Saint-Germain Hospital, Poissy, France
| | - Jean-Yves Peeltier
- Department of Biological Hematology, Poissy-Saint-Germain Hospital, Poissy, France
| | - Sandrine Canaple
- Department of Neurology, Amiens University Hospital, Amiens, France
| | - Bertrand Roussel
- Department of Biological Hematology, Amiens University Hospital, Amiens, France
| | | | - Emilie Scavazza
- Department of Biological Hematology, Perpignan Hospital, Perpignan, France
| | - Véronique Le Cam Duchez
- Normandie Univ, UNIROUEN, INSERM U1096, CHU de Rouen, Service d'Hématologie Biologique, Rouen, France
| |
Collapse
|
6
|
Siguret V, Boissier E, Maistre ED, Gouin-Thibault I, James C, Lasne D, Mouton C, Godon A, Nguyen P, Lecompte T, Ajzenberg N, Bauters A, Béjot Y, Crassard I, Dahmani B, Desconclois C, Flaujac C, Frère C, Godier A, Gruel Y, Hézard N, Jourdi G, Kuadjovi C, Laurichesse M, Mémier V, Mourey G, Reiner P, Tardy B, Toussaint-Hacquard M. GFHT Proposals On The Practical Use Of Argatroban - With Specifics Regarding Vaccine-Induced Immune Thrombotic Thrombocytopaenia (VITT). Anaesth Crit Care Pain Med 2021; 40:100963. [PMID: 34673303 DOI: 10.1016/j.accpm.2021.100963] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2021] [Accepted: 10/01/2021] [Indexed: 11/29/2022]
Abstract
Argatroban is a direct anti-IIa (thrombin) anticoagulant, administered as a continuous intravenous infusion; it has been approved in many countries for the anticoagulant management of heparin-induced thrombocytopaenia (HIT). Argatroban was recently proposed as the non-heparin anticoagulant of choice for the management of patients diagnosed with Vaccine-induced Immune Thrombotic Thrombocytopaenia (VITT). Immunoglobulins are also promptly intravenously administered in order to rapidly improve platelet count; concomitant therapy with steroids is also often considered. An ad hoc committee of the French Working Group on Haemostasis and Thrombosis members has worked on updated and detailed proposals regarding the management of anticoagulation with argatroban, based on previously released guidance for HIT, and adapted for VITT. In case of VITT, the initial dose to be preferred is 1.0 µg x kg-1 x min-1, with further dose-adjustments based on iterative and frequent clinical and laboratory assessments. It is strongly advised to involve a health practitioner experienced in the management of difficult cases in haemostasis. The first laboratory assessment should be performed 4 hours after the initiation of argatroban infusion, with further controls at 2-4-hour intervals until steady state, and at least once daily thereafter. Importantly, full anticoagulation should be rapidly achieved in case of widespread thrombosis. Cerebral vein thrombosis (which is typical of VITT) should not call for an overly cautious anticoagulation scheme. Argatroban administration requires baseline laboratory assessment and should rely on an anti-IIa assay to derive argatroban plasma levels using a dedicated calibration, with a target range between 0.5 and 1.5 µg/mL. Target argatroban plasma levels can be refined based on meticulous appraisal of risk factors for bleeding and thrombosis, on frequent reassessments of clinical status with appropriate vascular imaging, and on the changes in daily platelet counts. Regarding the use of aPTT, baseline value and possible causes for alterations of the clotting time must be taken into account. Specifically, in case of VITT, an aPTT ratio (patient's / mean normal clotting time) between 1.5 and 2.5 is suggested, to be refined according to the sensitivity of the reagent to the effect of a direct thrombin inhibitor. The sole use of aPTT is discouraged: one has to resort to a periodical check with an anti-IIa assay at least, with the help of a specialised laboratory if necessary. Dose modifications should proceed in a stepwise manner with 0.1 to 0.2 µg x kg-1 x min-1 up- or downward changes, taking into account the initial dose, laboratory results, and the whole individual setting. Nomograms are available to adjust the infusion rate. Haemoglobin level, platelet count, fibrinogen plasma level and liver tests should be periodically checked, depending on the clinical status, the more so when unstable.
Collapse
Affiliation(s)
- Virginie Siguret
- Hématologie biologique - Hôpital Lariboisière (AP-HP), UMR_S1140, Université de Paris, Paris, France.
| | - Elodie Boissier
- Laboratoire d'hématologie, Hôpital Laënnec, CHU de Nantes, France
| | | | | | - Chloé James
- Laboratoire d'hématologie, CHU de Bordeaux, Pessac, France
| | - Dominique Lasne
- Hématologie biologique - Hôpital Necker-Enfants malades (AP-HP), Paris, UMR_S1176 Université Paris Saclay, Le Kremlin Bicêtre, France
| | | | | | | | - Thomas Lecompte
- Départements de médecine, Hôpitaux Universitaires de Genève, Unité d'hémostase, & Faculté de Médecine - GpG, Université de Genève, Genève, Suisse
| | | | - Anne Bauters
- Service d'hématologie et transfusion, Université de Lille, CHU de Lille, Lille, France
| | | | - Isabelle Crassard
- Neurologie, Hôpital Lariboisière (APHP), FHU NeuroVasculaire, Université de Paris, Paris, France
| | - Bouhadjar Dahmani
- Hémostase et Thrombose, Centre Hospitalier Princesse Grace de Monaco, Monaco
| | | | - Claire Flaujac
- Laboratoire de biologie médicale, secteur hémostase, CH de Versailles, Le Chesnay, France
| | - Corinne Frère
- Hématologie Biologique, Hôpital Pitié Salpêtrière (AP-HP); Sorbonne Université, UMRS 1166, Institut hospitalo-universitaire ICAN, Paris, France
| | - Anne Godier
- Département d'Anesthésie Réanimation, Hôpital Européen Georges Pompidou (AP-HP), Paris, France
| | - Yves Gruel
- Hématologie biologique, CHU Tours, Tours, France
| | | | - Georges Jourdi
- Centre de recherche, Institut de Cardiologie de Montréal, Faculté de Pharmacie, Université de Montréal, Canada
| | - Charlène Kuadjovi
- Laboratoire du GCS Nord-Ouest Val d'Oise, CH Pontoise, Pontoise, France
| | | | - Vincent Mémier
- Laboratoire d'Hématologie, CHU Toulouse, Toulouse, France
| | - Guillaume Mourey
- Laboratoire d'Hématologie et d'Immunologie, Établissement Français du Sang Bourgogne -Franche-Comté, Besançon, France
| | - Peggy Reiner
- Service d'hématologie et transfusion, Université de Lille, CHU de Lille, Lille, France
| | - Brigitte Tardy
- INSERM U1059, Université J Monnet, Saint Etienne, France
| | | |
Collapse
|
7
|
Vayne C, Rollin J, Gruel Y, Pouplard C, Galinat H, Huet O, Mémier V, Geeraerts T, Marlu R, Pernod G, Mourey G, Fournel A, Cordonnier C, Susen S. PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia. N Engl J Med 2021; 385:376-378. [PMID: 34010527 PMCID: PMC8174029 DOI: 10.1056/nejmc2106383] [Citation(s) in RCA: 76] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
| | | | - Yves Gruel
- Tours University Hospital, Tours, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Castoldi E, Hézard N, Mourey G, Wichapong K, Poggi M, Ibrahim-Kosta M, Thomassen MCLGD, Fournel A, Hayward CPM, Alessi MC, Hackeng TM, Rosing J, Morange PE. Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon). J Thromb Haemost 2021; 19:1186-1199. [PMID: 33605529 DOI: 10.1111/jth.15274] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 01/04/2021] [Indexed: 01/01/2023]
Abstract
BACKGROUND Coagulation factor V (FV), present in plasma and platelets, has both pro- and anticoagulant functions. OBJECTIVE We investigated an FV-deficient patient (FV:C 3%, FV:Ag 4%) paradoxically presenting with recurrent venous thrombosis (11 events) instead of bleeding. METHODS/RESULTS Thrombophilia screening revealed only heterozygosity for the F2 20210G>A mutation. Although thrombin generation in the patient's platelet-poor plasma was suggestive of a hypocoagulable state, thrombin generation in the patient's platelet-rich plasma (PRP) was higher than in control PRP and extremely resistant to activated protein C (APC). This was partially attributable to the complete abolition of the APC-cofactor activity of FV and a marked reduction of plasma tissue factor pathway inhibitor antigen and activity. The patient was homozygous for a novel missense mutation (Ala2086Asp, FVBesançon ) that favors a "closed conformation" of the C2 domain, predicting impaired binding of FV(a) to phospholipids. Recombinant FVBesançon was hardly secreted, indicating that this mutation is responsible for the patient's FV deficiency. Model system experiments performed using highly diluted plasma as a source of FV showed that, compared with normal FVa, FVaBesançon has slightly (≤1.5-fold) unfavorable kinetic parameters (Km , Vmax ) of prothrombin activation, but also a lower rate of APC-catalyzed inactivation in the presence of protein S. CONCLUSIONS FVBesançon induces a hypercoagulable state via quantitative (markedly decreased FV level) and qualitative (phospholipid-binding defect) effects that affect anticoagulant pathways (anticoagulant activities of FV, FVa inactivation, tissue factor pathway inhibitor α level) more strongly than the prothrombinase activity of FVa. A possible specific role of platelet FV cannot be excluded.
Collapse
Affiliation(s)
- Elisabetta Castoldi
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands
| | - Nathalie Hézard
- Laboratory of Haematology, La Timone Hospital, Marseille, France
| | - Guillaume Mourey
- Department of Clinical Hemostasis, University Hospital of Besançon, Besançon, France
| | - Kanin Wichapong
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands
| | - Marjorie Poggi
- C2VN, INSERM, INRA, Aix Marseille University, Marseille, France
| | | | | | - Alexandra Fournel
- Department of Clinical Hemostasis, University Hospital of Besançon, Besançon, France
| | | | | | - Tilman M Hackeng
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands
| | - Jan Rosing
- Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands
| | | |
Collapse
|
9
|
Weil D, Di Martino V, Mourey G, Biichle S, Renaudin A, Laheurte C, Cypriani B, Delabrousse E, Grandclément E, Thévenot T, Saas P. Small Annexin V-Positive Platelet-Derived Microvesicles Affect Prognosis in Cirrhosis: A Longitudinal Study. Clin Transl Gastroenterol 2021; 12:e00333. [PMID: 33908373 PMCID: PMC8084097 DOI: 10.14309/ctg.0000000000000333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 02/17/2021] [Indexed: 12/26/2022] Open
Abstract
INTRODUCTION Microvesicles (MVs) with procoagulant properties may favor liver parenchymal extinction, then cirrhosis-related complications and mortality. In a longitudinal cohort of cirrhotic patients, we measured plasma levels of platelet-derived MVs (PMVs), endothelial-derived MVs, and red blood cell-derived MVs, expressing phosphatidylserine (annexin V-positive [AV+]) or not, and evaluated their impact on Model for End-Stage Liver Disease (MELD) score and transplant-free survival. METHODS MVs were quantified using flow cytometry in plasma from 90 noninfected cirrhotic patients and 10 healthy volunteers matched for age and sex. Impact of plasma microvesicle levels on 6-month transplant-free survival was assessed using log-rank tests and logistic regression. RESULTS Microvesicle levels, mostly platelet-derived, were 2.5-fold higher in healthy volunteers compared with cirrhotic patients. Circulating small AV+ PMV levels were lower in cirrhotic patients (P = 0.014) and inversely correlated with MELD scores (R = -0.28; P = 0.0065). During 1-year follow-up, 8 patients died and 7 underwent liver transplantation. In the remaining patients, circulating microvesicle levels did not change significantly. Six-month transplant-free survival was lower in patients with low baseline small AV+ PMV levels (72.6% vs 96.2%; P = 0.0007). In multivariate analyses adjusted for age, ascites, esophageal varices, encephalopathy, clinical decompensation, total platelet counts, MELD score, and/or Child-Pugh C stage, patients with lower small AV+ PMV levels had a significant 5- to 8-fold higher risk of 6-month death or liver transplant. Other PMV levels did not impact on survival. DISCUSSION Decreased circulating small AV+ PMV levels are associated with significantly lower transplant-free survival in cirrhotic patients independently of MELD score and platelet counts.
Collapse
Affiliation(s)
- Delphine Weil
- Service d'Hépatologie, CHU Jean Minjoz, Besançon, France
- EA 4266, Épigénétique des Infections Virales et des Maladies Inflammatoires EPILAB, Univ Bourgogne Franche-Comté, Besançon, France
| | - Vincent Di Martino
- Service d'Hépatologie, CHU Jean Minjoz, Besançon, France
- EA 4266, Épigénétique des Infections Virales et des Maladies Inflammatoires EPILAB, Univ Bourgogne Franche-Comté, Besançon, France
| | - Guillaume Mourey
- Univ. Bourgogne Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Etablissement Français du Sang Bourgogne Franche-Comté, INSERM, CIC-1431, Plateforme de BioMonitoring, Besançon, France
| | - Sabeha Biichle
- Univ. Bourgogne Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Etablissement Français du Sang Bourgogne Franche-Comté, INSERM, CIC-1431, Plateforme de BioMonitoring, Besançon, France
| | - Adeline Renaudin
- Univ. Bourgogne Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Etablissement Français du Sang Bourgogne Franche-Comté, INSERM, CIC-1431, Plateforme de BioMonitoring, Besançon, France
| | - Caroline Laheurte
- Univ. Bourgogne Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Etablissement Français du Sang Bourgogne Franche-Comté, INSERM, CIC-1431, Plateforme de BioMonitoring, Besançon, France
| | - Benoit Cypriani
- Service de Biochimie Médicale, CHU Jean Minjoz, Besançon, France
| | | | | | - Thierry Thévenot
- Service d'Hépatologie, CHU Jean Minjoz, Besançon, France
- EA 4266, Épigénétique des Infections Virales et des Maladies Inflammatoires EPILAB, Univ Bourgogne Franche-Comté, Besançon, France
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Etablissement Français du Sang Bourgogne Franche-Comté, INSERM, CIC-1431, Plateforme de BioMonitoring, Besançon, France
| |
Collapse
|
10
|
Marchi R, Neerman-Arbez M, Gay V, Mourey G, Fiore M, Mouton C, Gautier P, De Moerloose P, Casini A. Comparison of different activators of coagulation by turbidity analysis of hereditary dysfibrinogenemia and controls. Blood Coagul Fibrinolysis 2021; 32:108-114. [PMID: 33443927 DOI: 10.1097/mbc.0000000000001000] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Turbidity analysis is widely used as a quantitative technique in hereditary dysfibrinogenemia. We aimed to compare several coagulation triggers in hereditary dysfibrinogenemia and control plasmas. We included 20 patients with hereditary dysfibrinogenemia, 19 with hotspot mutations Aα Arg35His (n = 9), Aα Arg35Cys (n = 2), γ Arg301His (n = 6), γ Arg301Cys (n = 2), and one with Aα Phe27Tyr, and a commercial pooled normal plasma. Fibrin polymerization was activated by bovine or human thrombin or tissue factor (TF), in the presence or absence of tissue type plasminogen activator. The lag time (min), slope (mOD/s), maximum absorbance (MaxAbs, mOD), and area under the curve (AUCp, OD s) were calculated from the fibrin polymerization curves and the time for 50% clot degradation (T50, min), AUCf (OD s) and the overall fibrinolytic potential from fibrinolysis curves. The lag time was significantly shorter and AUC increased in Aα Arg35His patients with bovine thrombin as compared with human thrombin. The MaxAbs and AUCp were significantly higher in γArg301His patients with bovine thrombin compared with human thrombin. Fibrin polymerization parameters of patients' samples were closer to those of control when assessed with TF compared with both human and bovine thrombin. T50 and overall fibrinolytic potential were similar in all samples regardless of the coagulation trigger used, however, with TF the AUCf of Aα Arg35His and γ Arg301His groups were significantly decreased compared with control. Bovine and human thrombin cannot be used equally for studying fibrin polymerization in hotspot hereditary dysfibrinogenemia or control plasmas.
Collapse
Affiliation(s)
- Rita Marchi
- Experimental Medicine, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela.,Faculty of Medicine
| | - Marguerite Neerman-Arbez
- Department of Genetic Medicine and Development, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Valérie Gay
- Haemophilia Treatment Centre, Centre hospitalier Métropole Savoie, Chambery
| | - Guillaume Mourey
- Haemophilia Treatment Centre, University Hospital of Besançon.,Hemostasis Laboratory, Etablissement Français du Sang, Besançon
| | - Mathieu Fiore
- Service d'Hématologie biologique, CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque, Bordeaux
| | - Christine Mouton
- Service d'Hématologie biologique, CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque, Bordeaux
| | | | | | - Alessandro Casini
- Faculty of Medicine.,Division of Angiology and Hemostasis, University Hospitals of Geneva, Geneva, Switzerland
| |
Collapse
|
11
|
Mouhat B, Besutti M, Bouiller K, Grillet F, Monnin C, Ecarnot F, Behr J, Capellier G, Soumagne T, Pili-Floury S, Besch G, Mourey G, Lepiller Q, Chirouze C, Schiele F, Chopard R, Meneveau N. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J 2020; 56:13993003.01811-2020. [PMID: 32907890 PMCID: PMC7487272 DOI: 10.1183/13993003.01811-2020] [Citation(s) in RCA: 81] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 07/01/2020] [Indexed: 01/08/2023]
Abstract
Background Coronavirus disease 2019 (COVID-19) may predispose to venous thromboembolism. We determined factors independently associated with computed tomography pulmonary angiography (CTPA)-confirmed pulmonary embolism (PE) in hospitalised severe COVID-19 patients. Methods Among all (n=349) patients hospitalised for COVID-19 in a university hospital in a French region with a high rate of COVID-19, we analysed patients who underwent CTPA for clinical signs of severe disease (oxygen saturation measured by pulse oximetry ≤93% or breathing rate ≥30 breaths·min−1) or rapid clinical worsening. Multivariable analysis was performed using Firth penalised maximum likelihood estimates. Results 162 (46.4%) patients underwent CTPA (mean±sd age 65.6±13.0 years; 67.3% male (95% CI 59.5–75.5%). PE was diagnosed in 44 (27.2%) patients. Most PEs were segmental and the rate of PE-related right ventricular dysfunction was 15.9%. By multivariable analysis, the only two significant predictors of CTPA-confirmed PE were D-dimer level and the lack of any anticoagulant therapy (OR 4.0 (95% CI 2.4–6.7) per additional quartile and OR 4.5 (95% CI 1.1–7.4), respectively). Receiver operating characteristic curve analysis identified a D-dimer cut-off value of 2590 ng·mL−1 to best predict occurrence of PE (area under the curve 0.88, p<0.001, sensitivity 83.3%, specificity 83.8%). D-dimer level >2590 ng·mL−1 was associated with a 17-fold increase in the adjusted risk of PE. Conclusion Elevated D-dimers (>2590 ng·mL−1) and absence of anticoagulant therapy predict PE in hospitalised COVID-19 patients with clinical signs of severity. These data strengthen the evidence base in favour of systematic anticoagulation, and suggest wider use of D-dimer guided CTPA to screen for PE in acutely ill hospitalised patients with COVID-19. We studied predictors of pulmonary embolism in severe COVID-19 and found that D-dimer level and lack of any anticoagulant therapy were associated with a 17-fold and four-fold increase in PE, respectively, in COVID-19 patients with clinical signs of severityhttps://bit.ly/2ETfAfo
Collapse
Affiliation(s)
- Basile Mouhat
- Dept of Cardiology, University Hospital, Besançon, France
| | | | - Kevin Bouiller
- Infectious and Tropical Diseases Unit, University Hospital, Besançon, France.,UMR CNRS 6249 Chrono-Environnement, University of Franche-Comte, Besancon, France
| | - Franck Grillet
- Dept of Radiology, Besançon University Hospital, Besançon, France
| | - Charles Monnin
- Dept of Cardiology, University Hospital, Besançon, France
| | - Fiona Ecarnot
- Dept of Cardiology, University Hospital, Besançon, France.,Research Unit EA3920, University of Franche-Comte, Besancon, France
| | - Julien Behr
- Dept of Radiology, Besançon University Hospital, Besançon, France
| | - Gilles Capellier
- Research Unit EA3920, University of Franche-Comte, Besancon, France.,Medical Intensive Care Unit, University Hospital, Besançon, France
| | - Thibaud Soumagne
- Medical Intensive Care Unit, University Hospital, Besançon, France
| | - Sébastien Pili-Floury
- Research Unit EA3920, University of Franche-Comte, Besancon, France.,Anesthesia and Surgical Intensive Care Unit, University Hospital, Besançon, France
| | - Guillaume Besch
- Research Unit EA3920, University of Franche-Comte, Besancon, France.,Anesthesia and Surgical Intensive Care Unit, University Hospital, Besançon, France
| | - Guillaume Mourey
- Hematology Unit, University Hospital, Besançon, France.,INSERM UMR 1098, University of Franche-Comte, Besancon, France
| | | | - Catherine Chirouze
- Infectious and Tropical Diseases Unit, University Hospital, Besançon, France.,UMR CNRS 6249 Chrono-Environnement, University of Franche-Comte, Besancon, France
| | - François Schiele
- Dept of Cardiology, University Hospital, Besançon, France.,Research Unit EA3920, University of Franche-Comte, Besancon, France
| | - Romain Chopard
- Dept of Cardiology, University Hospital, Besançon, France.,Research Unit EA3920, University of Franche-Comte, Besancon, France.,Both authors contributed equally
| | - Nicolas Meneveau
- Dept of Cardiology, University Hospital, Besançon, France.,Research Unit EA3920, University of Franche-Comte, Besancon, France.,Both authors contributed equally
| |
Collapse
|
12
|
Oseev A, Lecompte T, Remy-Martin F, Mourey G, Chollet F, de Boiseaumarie BLR, Rouleau A, Bourgeois O, de Maistre E, Elie-Caille C, Manceau JF, Boireau W, Leblois T. Assessment of Shear-Dependent Kinetics of Primary Haemostasis With a Microfluidic Acoustic Biosensor. IEEE Trans Biomed Eng 2020; 68:2329-2338. [PMID: 33055022 DOI: 10.1109/tbme.2020.3031542] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Primary haemostasis is a complex dynamic process, which involves in-flow interactions between platelets and sub-endothelial matrix at the area of the damaged vessel wall. It results in a first haemostatic plug, which stops bleeding, before coagulation ensues and consolidates it. The diagnosis of primary haemostasis defect would benefit from evaluation of the whole sequence of mechanisms involved in platelet plug formation in flow. This work proposes a new approach that is based on characterization of the shear-dependent kinetics that enables the evaluation of the early stages of primary haemostasis. We used a label-free method with a quartz crystal microbalance (QCM) biosensor to measure the platelet deposits over time onto covalently immobilized type I fibrillar collagen. We defined three metrics: total frequency shift, lag time, and growth rate. The measurement was completed at four predefined shear rates prevailing in small vessels (500, 770, 1000 and 1500 s-1) during five minutes of perfusion with anticoagulated normal whole blood. The rate of the frequency shift over the first five minutes was strongly influenced by shear rate conditions, presenting a maximum around 770 s-1, and varying by a factor larger than three in the studied shear rate range. To validate the biosensor signal, the total frequency shift was compared to results obtained by atomic force microscopy (AFM) on final platelet deposits. The results show that shear-dependent kinetic assays are promising as an advanced method for screening of primary haemostasis.
Collapse
|
13
|
Soumagne T, Winiszewski H, Besch G, Mahr N, Senot T, Costa P, Grillet F, Behr J, Mouhat B, Mourey G, Fournel A, Meneveau N, Samain E, Capellier G, Piton G, Pili-Floury S. Pulmonary embolism among critically ill patients with ARDS due to COVID-19. Respir Med Res 2020; 78:100789. [PMID: 33022510 PMCID: PMC7494436 DOI: 10.1016/j.resmer.2020.100789] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 08/25/2020] [Accepted: 08/31/2020] [Indexed: 02/06/2023]
Affiliation(s)
- T Soumagne
- Medical Intensive Care Unit, Besançon University Hospital, Besançon, France.
| | - H Winiszewski
- Medical Intensive Care Unit, Besançon University Hospital, Besançon, France
| | - G Besch
- Anaesthesiology and Surgical Intensive Care Unit, Besançon University Hospital, Besançon, France
| | - N Mahr
- Medical Intensive Care Unit, Besançon University Hospital, Besançon, France
| | - T Senot
- Anaesthesiology and Surgical Intensive Care Unit, Besançon University Hospital, Besançon, France
| | - P Costa
- Surgical and Medical Vascular Unit, Besançon University Hospital, Besançon, France
| | - F Grillet
- Department of Radiology, Besançon University Hospital, Besançon, France
| | - J Behr
- Department of Radiology, Besançon University Hospital, Besançon, France
| | - B Mouhat
- Cardiology Unit, Besançon University Hospital, Besançon, France
| | - G Mourey
- Hematology Unit, Besançon University Hospital, Besançon, France
| | - A Fournel
- Hematology Unit, Besançon University Hospital, Besançon, France
| | - N Meneveau
- Cardiology Unit, Besançon University Hospital, Besançon, France
| | - E Samain
- Anaesthesiology and Surgical Intensive Care Unit, Besançon University Hospital, Besançon, France
| | - G Capellier
- Medical Intensive Care Unit, Besançon University Hospital, Besançon, France
| | - G Piton
- Medical Intensive Care Unit, Besançon University Hospital, Besançon, France
| | - S Pili-Floury
- Anaesthesiology and Surgical Intensive Care Unit, Besançon University Hospital, Besançon, France
| |
Collapse
|
14
|
Vilar R, Casini A, Fournel A, Mourey G, Neerman-Arbez M. Identification and expression of a novel heterozygous frameshift mutation in FGA accounting for congenital hypofibrinogenemia in carriers of severe hemophilia A. Thromb Res 2020; 193:5-8. [PMID: 32497950 DOI: 10.1016/j.thromres.2020.05.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Revised: 04/15/2020] [Accepted: 05/26/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Rui Vilar
- Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Switzerland
| | - Alessandro Casini
- Division of Angiology and Hemostasis, University Hospitals, University of Geneva Faculty of Medicine, Switzerland
| | - Alexandra Fournel
- Haemophilia Treatment Centre, University Hospital of Besançon, Besançon, France
| | - Guillaume Mourey
- Haemophilia Treatment Centre, University Hospital of Besançon, Besançon, France; Hemostasis Laboratory, Etablissement Français du Sang, Besançon, France
| | - Marguerite Neerman-Arbez
- Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, Switzerland; iGE3, Institute of Genetics and Genomics in Geneva, Geneva, Switzerland.
| |
Collapse
|
15
|
Pouplard C, Galinat H, Ternisien C, Blanc Jouvan F, De Maistre E, Duchemin J, Flaujac C, Hézard N, Grand F, Le Cam‐Duchez V, Marlu R, Mourey G, Nedelec F, Pineau‐Vincent F, Repesse Y, Stépanian A, Szymezak J, Voisin S, Voyer AL, Jeanpierre E, Lasne D. Multicentre evaluation of
CK
Prest
®
for assaying plasma levels of factor IX fused with albumin (Idelvion
®
). Haemophilia 2019; 25:e327-e330. [DOI: 10.1111/hae.13812] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 06/04/2019] [Accepted: 06/10/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Claire Pouplard
- EA7501 GICC University of Tours Tours France
- Department of Haematology‐Haemostasis University Hospital of Tours Tours France
| | - Hubert Galinat
- Department of Haemostasis University Hospital of Brest Brest France
| | | | | | | | - Jérôme Duchemin
- Department of Haemostasis University Hospital of Paris Cochin Paris France
| | - Claire Flaujac
- Department of Haemostasis Hospital of Versailles Versailles France
| | - Nathalie Hézard
- Department of Haemostasis Hospital of Marseille Marseille France
| | - François Grand
- Department of Haemostasis University Hospital of Poitiers Poitiers France
| | | | - Raphael Marlu
- Department of Haemostasis University Hospital of Grenoble Grenoble France
| | | | - Fabienne Nedelec
- Department of Haemostasis University Hospital of Rennes Rennes France
| | | | - Yohann Repesse
- Department of Haemostasis University Hospital of Caen Caen France
| | - Alain Stépanian
- Department of Haemostasis University Hospital of Paris Lariboisière Paris France
| | - Jean Szymezak
- Department of Haemostasis University Hospital of Reims Reims France
| | - Sophie Voisin
- Department of Haemostasis University Hospital of Toulouse Toulouse France
| | - Anne Lise Voyer
- Department of Haemostasis University Hospital of Amiens Amiens France
| | | | - Dominique Lasne
- Department of biologic Haematology AP‐HP Hôpital Necker Paris INSERM UMR‐S1176 University Paris Sud University Paris‐Saclay Le Kremlin Bicêtre France
| | | |
Collapse
|
16
|
Weil D, Pais de Barros JP, Mourey G, Laheurte C, Cypriani B, Badet N, Delabrousse E, Grandclément E, Di Martino V, Saas P, Lagrost L, Thévenot T. Circulating levels of 3-hydroxymyristate, a direct quantification of endotoxaemia in noninfected cirrhotic patients. Liver Int 2019; 39:106-114. [PMID: 29931819 DOI: 10.1111/liv.13916] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2018] [Accepted: 06/15/2018] [Indexed: 12/12/2022]
Abstract
BACKGROUND & AIMS The quantification of lipopolysaccharide (LPS) in biological fluids is challenging. We aimed to measure plasma LPS concentration using a new method of direct quantification of 3-hydroxymyristate (3-HM), a lipid component of LPS, and to evaluate correlations between 3-HM and markers of liver function, endothelial activation, portal hypertension and enterocyte damage. METHODS Plasma from 90 noninfected cirrhotic patients (30 Child-Pugh [CP]-A, 30 CP-B, 30 CP-C) was prospectively collected. The concentration of 3-HM was determined by high-performance liquid chromatography coupled with mass spectrometry. RESULTS 3-HM levels were higher in CP-C patients (CP-A/CP-B/CP-C: 68/70/103 ng/mL, P = 0.005). Patients with severe acute alcoholic hepatitis (n = 16; 113 vs 74 ng/mL, P = 0.012), diabetic patients (n = 22; 99 vs 70 ng/mL, P = 0.028) and those not receiving beta blockers (n = 44; 98 vs 72 ng/mL, P = 0.034) had higher levels of 3-HM. We observed a trend towards higher baseline levels of 3-HM in patients with hepatic encephalopathy (n = 7; 144 vs 76 ng/mL, P = 0.45) or SIRS (n = 10; 106 vs 75 ng/mL, P = 0.114). In multivariate analysis, high levels of 3-HM were associated with CP (OR = 4.39; 95%CI = 1.79-10.76) or MELD (OR = 8.24; 95%CI = 3.19-21.32) scores. Patients dying from liver insufficiency (n = 6) during a 12-month follow-up had higher baseline levels of 3-HM (106 vs 75 ng/mL, P = 0.089). CONCLUSIONS In noninfected cirrhotic patients, 3-HM arises more frequently with impairment of liver function, heavy alcohol consumption, diabetic status, nonuse of beta blockers and a trend towards poorer outcome is also observed. The direct mass measurement of LPS using 3-HM appears reliable to detect transient endotoxaemia and promising to manage the follow-up of cirrhotic patients.
Collapse
Affiliation(s)
- Delphine Weil
- Service d'Hépatologie, CHU Jean Minjoz, Besançon, France.,UPRES EA4266, Laboratoire Pathogènes & Inflammation/EPILAB, Université de Bourgogne Franche-Comté, Besançon, France
| | - Jean-Paul Pais de Barros
- INSERM, LNC UMR 1231, Université de Bourgogne Franche-Comté, Dijon, France.,LipSTIC LabEx, Plateforme de BioMonitoring, Besançon, France
| | - Guillaume Mourey
- INSERM Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Plateforme de BioMonitoring, Univ.Bourgogne Franche-Comté, Besançon, France
| | - Caroline Laheurte
- INSERM Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Plateforme de BioMonitoring, Univ.Bourgogne Franche-Comté, Besançon, France
| | - Benoit Cypriani
- Service de Biochimie Médicale, CHU Jean Minjoz, Besançon, France
| | - Nicolas Badet
- Service de Radiologie, CHU Jean Minjoz, Besançon, France
| | | | | | - Vincent Di Martino
- Service d'Hépatologie, CHU Jean Minjoz, Besançon, France.,UPRES EA4266, Laboratoire Pathogènes & Inflammation/EPILAB, Université de Bourgogne Franche-Comté, Besançon, France
| | - Philippe Saas
- INSERM Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, LipSTIC LabEx, Plateforme de BioMonitoring, Univ.Bourgogne Franche-Comté, Besançon, France
| | - Laurent Lagrost
- INSERM, LNC UMR 1231, Université de Bourgogne Franche-Comté, Dijon, France.,LipSTIC LabEx, Plateforme de BioMonitoring, Besançon, France
| | - Thierry Thévenot
- Service d'Hépatologie, CHU Jean Minjoz, Besançon, France.,UPRES EA4266, Laboratoire Pathogènes & Inflammation/EPILAB, Université de Bourgogne Franche-Comté, Besançon, France
| |
Collapse
|
17
|
Ravanat C, Dupuis A, Marpaux N, Naegelen C, Mourey G, Isola H, Laforêt M, Morel P, Gachet C. In vitro
quality of amotosalen‐
UVA
pathogen‐inactivated mini‐pool plasma prepared from whole blood stored overnight. Vox Sang 2018; 113:622-631. [DOI: 10.1111/vox.12697] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Revised: 06/26/2018] [Accepted: 06/28/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Catherine Ravanat
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | - Arnaud Dupuis
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | | | | | - Guillaume Mourey
- EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
- Université Bourgogne Franche Comté INSERM EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
| | - Herve Isola
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | - Michel Laforêt
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| | - Pascal Morel
- EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
- Université Bourgogne Franche Comté INSERM EFS Bourgogne‐Franche‐Comté UMR1098 Besançon France
| | - Christian Gachet
- Université de Strasbourg INSERM EFS Grand‐Est BPPS UMR‐S1255 FMTS Strasbourg France
| |
Collapse
|
18
|
Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P. Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study. BMJ Open 2018; 8:e022409. [PMID: 30049701 PMCID: PMC6067371 DOI: 10.1136/bmjopen-2018-022409] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 06/08/2018] [Accepted: 06/14/2018] [Indexed: 01/14/2023] Open
Abstract
INTRODUCTION Severe haemophilia is a rare disease characterised by spontaneous bleeding from early childhood, which may lead to various complications, especially in joints. It is nowadays possible to avoid these complications thanks to substitutive therapies for which the issue of adherence is major. The transition from adolescence to adulthood in young people with severe haemophilia is a critical period as it is associated with a high risk of lack of adherence to healthcare, which might have serious consequences on daily activities and on quality of life. METHODS AND ANALYSIS We present the protocol for a cross-sectional, observational, multicentric study to assess the differences between adolescents and young adults with severe haemophilia in France through the transition process, especially on adherence to healthcare. This study is based on a mixed methods design, with two complementary and consecutive phases, comparing data from a group of adolescents (aged 14-17 years) with those from a group of young adults (aged 20-29 years). The quantitative phase focuses on the determinants (medical, organisational, sociodemographic and social and psychosocial and behavioural factors) of adherence to healthcare (considered as a marker of the success of transition). The qualitative phase explores participants' views in more depth to explain and refine the results from the quantitative phase. Eligible patients are contacted by the various Haemophilia Treatment Centres participating in the French national registry FranceCoag. ETHICS AND DISSEMINATION The study was approved by the French Ethics Committee and by the French National Agency for Medicines and Health Products Safety (number: 2016-A01034-47). Study findings will be disseminated to the scientific and medical community in peer-reviewed journals and presented at scientific meetings. Results will be popularised to be communicated via the French association for people with haemophilia to participants and to the general public. TRIAL REGISTRATION NUMBER NCT02866526; Pre-results.
Collapse
Affiliation(s)
| | - Natacha Rosso-Delsemme
- LPCPP, Aix Marseille Unviersity, Aix-en-Provence, France
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
| | | | - Karine Baumstarck
- CERESS, Aix Marseille University, Marseille, France
- FranceCoag Network, Marseille, France
| | - Vanessa Milien
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
- FranceCoag Network, Marseille, France
| | - Laurent Ardillon
- Haemophilia Treatment Centre, University Hospital of Tours, Tours, France
| | - Sophie Bayart
- Haemophilia Treatment Centre, University Hospital of Rennes, Rennes, France
| | - Claire Berger
- Haemophilia Treatment Centre, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Marie-Anne Bertrand
- Haemophilia Treatment Centre, University Hospital of Besançon, Besançon, France
| | | | | | - Sabine Castet
- Haemophilia Treatment Centre, University Hospital of Bordeaux, Bordeaux, France
| | - Pierre Chamouni
- Haemophilia Treatment Centre, University Hospital of Rouen, Rouen, France
| | | | | | - Dominique Desprez
- Haemophilia Treatment Centre, University Regional Hospital of Strasbourg, Strasbourg, France
| | - Céline Falaise
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
| | - Birgit Frotscher
- Haemophilia Treatment Centre, University Hospital of Nancy, Nancy, France
| | - Valérie Gay
- Haemophilia Treatment Centre, Hospital of Chambery, Chambery, France
| | - Jenny Goudemand
- Haemophilia Treatment Centre, University Regional Hospital of Lille, Lille, France
| | - Yves Gruel
- Haemophilia Treatment Centre, University Hospital of Tours, Tours, France
| | - Benoît Guillet
- Haemophilia Treatment Centre, University Hospital of Rennes, Rennes, France
| | - Annie Harroche
- Haemophilia Treatment Centre, Hospital Necker, Assistance Publique—Hopitaux de Paris, Paris, France
| | - Abel Hassoun
- Haemophilia Treatment Centre, Hospital of Simone Veil d’Eaubonne, Montmorency, France
| | - Yoann Huguenin
- Haemophilia Treatment Centre, University Hospital of Bordeaux, Bordeaux, France
| | - Thierry Lambert
- Haemophilia Treatment Centre, Hospital Bicêtre, Assistance Publique—Hopitaux de Paris, Paris, France
| | - Aurélien Lebreton
- Haemophilia Treatment Centre, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France
| | - Anne Lienhart
- Haemophilia Treatment Centre, Hospital Edouard Herriot, University Hospital of Lyon, Lyon, France
| | - Michèle Martin
- Haemophilia Treatment Centre, University Hospital of Nancy, Nancy, France
| | - Sandrine Meunier
- Haemophilia Treatment Centre, Hospital Edouard Herriot, University Hospital of Lyon, Lyon, France
| | - Fabrice Monpoux
- Haemophilia Treatment Centre, University Hospital of Nice, Nice, France
| | - Guillaume Mourey
- Haemophilia Treatment Centre, University Hospital of Besançon, Besançon, France
| | - Claude Negrier
- Haemophilia Treatment Centre, Hospital Edouard Herriot, University Hospital of Lyon, Lyon, France
| | - Philippe Nguyen
- Haemophilia Treatment Centre, University Hospital of Reims, Reims, France
| | - Placide Nyombe
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Caroline Oudot
- Haemophilia Treatment Centre, University Hospital of Limoges, Limoges, France
| | | | - Benoît Polack
- Haemophilia Treatment Centre, University Hospital of Grenoble, Grenoble, France
| | - Anne Rafowicz
- Haemophilia Treatment Centre, Hospital of Versailles, Versailles, France
- Haemophilia Treatment Centre, Hospital Bicêtre, Assistance Publique—Hopitaux de Paris, Paris, France
| | - Antoine Rauch
- Haemophilia Treatment Centre, University Regional Hospital of Lille, Lille, France
| | - Delphine Rivaud
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Pascale Schneider
- Haemophilia Treatment Centre, University Hospital of Rouen, Rouen, France
| | - Alexandra Spiegel
- Haemophilia Treatment Centre, University Regional Hospital of Strasbourg, Strasbourg, France
| | - Cecile Stoven
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Brigitte Tardy
- Haemophilia Treatment Centre, University Hospital of Saint-Etienne, Saint-Etienne, France
| | - Marc Trossaërt
- Haemophilia Treatment Centre, University Hospital of Nantes, Nantes, France
| | | | - Stéphane Vanderbecken
- Haemophilia Treatment Centre, University Hospital of Reunion, Reunion Island, France
| | - Fabienne Volot
- Haemophilia Treatment Centre, University Hospital of Dijon, Dijon, France
| | | | - Bénédicte Wibaut
- Haemophilia Treatment Centre, University Regional Hospital of Lille, Lille, France
| | - Tanguy Leroy
- CERESS, Aix Marseille University, Marseille, France
- Social Psychology Research Group (GRePS EA 4163), Lumière Lyon 2 University, Lyon, France
| | - Thomas Sannie
- French Patients' Association for People with Haemophilia (AFH), Paris, France
| | - Hervé Chambost
- Department of Paediatric Haematology, Children Hospital La Timone, APHM, Marseille, France
- FranceCoag Network, Marseille, France
| | - Pascal Auquier
- CERESS, Aix Marseille University, Marseille, France
- FranceCoag Network, Marseille, France
| |
Collapse
|
19
|
Moreau J, Pelletier F, Biichle S, Mourey G, Puyraveau M, Badet N, Caubet M, Laresche C, Garnache-Ottou F, Saas P, Seilles E, Aubin F. Increased levels of circulating platelet-derived microparticles are associated with metastatic cutaneous melanoma. Exp Dermatol 2017; 26:961-963. [PMID: 28266752 DOI: 10.1111/exd.13339] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/14/2017] [Indexed: 11/30/2022]
Abstract
We investigated the plasma levels of PMPs in patients with 45 stage III and 45 stage IV melanoma. PMPs were characterised by flow cytometry and their thrombogenic activity. We also investigated the link between PMPs circulating levels and tumor burden. The circulating levels of PMPs were significantly higher in stage IV (8500 μL-1 ) than in patients with stage III (2041 μL-1 ) melanoma (P=.0001). We calculated a highly specific (93.3%) and predictive (91.7%) cut-off value (5311 μL-1 ) allowing the distinction between high-risk stage III and metastatic stage IV melanoma. The thrombogenic activity of PMPs was significantly higher in patients with stage IV melanoma (clotting time: 40.7 second vs 65 second, P=.0001). There was no significant association between the radiological tumoral syndrome and the plasma level of PMPs. Our data suggest the role of PMPs in metastatic progression of melanoma.
Collapse
Affiliation(s)
- Joséphine Moreau
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,Department of Dermatology, University Hospital, Besançon, France
| | - Fabien Pelletier
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,Department of Dermatology, University Hospital, Besançon, France
| | - Sabeha Biichle
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France
| | - Guillaume Mourey
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France
| | - Marc Puyraveau
- Clinical Methodology Center, Besançon University Hospital, Besançon, France
| | - Nicolas Badet
- Department of Radiology, Besançon University Hospital, Besançon, France
| | - Matthieu Caubet
- Department of Radiotherapy, Besançon University Hospital, Besançon, France
| | - Claire Laresche
- Department of Dermatology, University Hospital, Besançon, France
| | - Francine Garnache-Ottou
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France
| | - Philippe Saas
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France
| | - Estelle Seilles
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,Etablissement Français du Sang Bourgogne Franche Comte, Besançon, France
| | - François Aubin
- INSERM UMR 1098, University of Bourgogne Franche Comté, Besançon, France.,EA3181, University of Bourgogne Franche Comté, Besançon, France
| |
Collapse
|
20
|
Gamonet C, Mourey G, Aupet S, Biichle S, Petitjean R, Vidal C, Pugin A, Naegelen C, Tiberghien P, Morel P, Angelot-Delettre F, Seilles E, Saas P, Bardiaux L, Garnache-Ottou F. How to quantify microparticles in RBCs? A validated flow cytometry method allows the detection of an increase in microparticles during storage. Transfusion 2017; 57:504-516. [DOI: 10.1111/trf.13989] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Revised: 10/19/2016] [Accepted: 11/08/2016] [Indexed: 12/16/2022]
Affiliation(s)
- Clémentine Gamonet
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
| | - Guillaume Mourey
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
- Hematology Laboratory; Établissement Français du Sang (EFS) Bourgogne/Franche-Comté
| | - Sophie Aupet
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
| | - Sabéha Biichle
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
| | - Régis Petitjean
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
| | - Chrystelle Vidal
- INSERM Centre d'Investigation Clinique-1431, Centre Hospitalier Régional Universitaire de Besançon Jean Minjoz
| | - Aurore Pugin
- INSERM Centre d'Investigation Clinique-1431, Centre Hospitalier Régional Universitaire de Besançon Jean Minjoz
| | | | - Pierre Tiberghien
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
- EFS Bourgogne/Franche-Comté; Besançon France
| | | | - Fanny Angelot-Delettre
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
| | - Estelle Seilles
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
- Hematology Laboratory; Établissement Français du Sang (EFS) Bourgogne/Franche-Comté
| | - Philippe Saas
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
| | | | - Francine Garnache-Ottou
- Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1098, Bourgogne Franche-Comté
- EFS Bourgogne/Franche-Comté; Besançon France
- Hematology Laboratory; Établissement Français du Sang (EFS) Bourgogne/Franche-Comté
| |
Collapse
|
21
|
Bougouin W, Marijon E, Planquette B, Karam N, Dumas F, Celermajer D, Jost D, Lamhaut L, Beganton F, Cariou A, Meyer G, Jouven X, Bureau C, Charpentier J, Salem OBH, Guillemet L, Arnaout M, Ferre A, Geri G, Mongardon N, Pène F, Chiche JD, Mira JP, Labro G, Belon F, Luu VP, Chenet J, Besch G, Puyraveau M, Piton G, Capellier G, Martin M, Lascarrou JB, Le Thuaut A, Lacherade JC, Martin-Lefèvre L, Fiancette M, Vinatier I, Lebert C, Bachoumas K, Yehia A, Henry-Laguarrigue M, Colin G, Reignier J, Privat E, Escutnaire J, Dumont C, Baert V, Vilhelm C, Hubert H, Robert-Edan V, Lakhal K, Quartin A, Hobbs B, Cely C, Bell C, Pham T, Schein R, Geng Y, Ng C, Ehrmann S, Gandonnière CS, Boisramé-Helms J, Le Tilly O, De Bretagne IB, Mercier E, Mankikian J, Bretagnol A, Meziani F, Halimi JM, Le Guellec CB, Gaudry S, Hajage D, Tubach F, Pons B, Boulet E, Boyer A, Chevrel G, Lerolle N, Carpentier D, de Prost N, Lautrette A, Mayaux J, Nseir S, Ricard JD, Dreyfuss D, Robert R, Garzotto F, Kipnis E, Tetta C, Ronco C, Schnell D, Aurelie B, Reynaud M, Clec’h C, Benyamina M, Vincent F, Mariat C, Bornstain C, Gloulou O, Boussarsar M, Zelmat SA, Batouche DD, Chaffi B, Mazour F, Benatta N, Fathallah I, Aloui R, Zoubli A, Rouleau S, Kouraichi N, Fathallah I, Kouraichi N, Salem S, Vicaut E, Megarbane B, Ambroise D, Loriot AM, Bourgogne E, Megarbane B, Leroy C, Ghadhoune H, Jihene G, Trabelsi I, Allouche H, Brahmi H, Samet M, Ghord HE, Lebeau R, Laplanche JL, Benturquia N, Cohen Y, Megarbane B, Blel Y, M’rad A, Essafi F, Benabderrahim A, Jouffroy R, Resiere D, Sanchez B, Inamo J, Megarbane B, Morel J, Batouche DD, Zerhouni A, Tabeliouna K, Negadi A, Mentouri Z, Le Gall F, Hanouz JL, Normand H, Khoury A, Sall FS, Legrand M, De Luca A, Pugin A, Pazart L, Vidal C, Leroux F, Khoury A, L’Her E, Marjanovic N, Khoury A, Desmettre T, Terreaux J, Lambert C, Ragey SP, Baboi L, Bazin JE, Koffel C, Dhonneur G, Bouzit Z, Bradai L, Ayed IB, Aissa F, Darmon M, Haouache H, Marechal Y, Biston P, Piagnerelli M, Bortolotti P, Colling D, Colas V, Voisin B, Dewavrin F, Onimus T, Cantier M, Girardie P, Saulnier F, Urbina T, Nguyen Y, Druoton AL, Soudant M, Barraud D, Conrad M, Cravoisy-Popovic A, Nace L, Morisot A, Bollaert PE, Martin R, Bitker L, Richard JC, Brossier D, Goyer I, Marquis C, Lampin M, Duhamel A, Béhal H, Guérot E, Dhaoui T, Godeffroy V, Devouge E, Evrard D, Delepoulle F, Racoussot S, Grandbastien B, Lampin M, Heilbronner C, Roy E, Canet E, Masson A, Hadchouel-Duvergé A, Rigourd V, Delacroix E, Wroblewski I, Pin I, Ego A, Payen V, Debillon T, Millet A, De Montmollin E, Denot J, Berthelot V, Thueux E, Reymond M, De Larrard A, Amblard A, Leger PL, Aoul NT, Lemiale V, Oziel J, Voiriot G, Brule N, Moreau AS, Marhbène T, Sellami S, Jamoussi A, Ayed S, Mhiri E, Slim L, Khelil JB, Besbes M, Neuville M, Chawki S, Hamdi A, Ciroldi M, Cottereau A, Obadia E, Zerbib Y, Andrejak C, Ricome S, Dupont H, Baudin F, Timsit JF, Dureau P, Tanguy A, Arbelot C, Ben HK, Charfeddine A, Granger B, Laporte L, Hermetet C, Regaieg K, Khemakhem R, Sonneville R, Chelly H, Cheikh CM, Mountij H, Rghioui K, Haddad W, Cherkab R, Barrou H, Naima A, bennani OM, Regaieg K, Fayssoil A, Douib A, Samet A, Cungi PJ, Nguyen C, Cotte J, D’aranda E, Meaudre E, Avaro JP, Slaoui MT, Mokline A, Stojkovic T, Rahmani I, Laajili A, Amri H, Gharsallah L, Gasri B, Tlaili S, Hammouda R, Messadi AA, Behin A, Ogna A, Lofaso F, Laforet P, Wahbi K, Prigent H, Duboc D, Orlikowski D, Eymard B, Annane D, Le Guennec L, Cholet C, Bréchot N, Hekimian G, Besset S, Lebreton G, Nieszkowska A, Trouillet JL, Leprince P, Combes A, Luyt CE, Griton M, Sesay M, De Panthou NS, Bienvenu T, Biais M, Nouette-Gaulain K, Fossat G, Baudin F, Coulanges C, Bobet S, Dupont A, Courtes L, Benzekri D, Kamel T, Muller G, Bercault N, Barbier F, Runge I, Skarzynski M, Mathonnet A, Boulain T, Jouan Y, Teixera N, Hassen-Khodja C, Guillon A, Gaborit C, Grammatico-Guillon L, Rebière C, Azoulay E, Misset B, Ruckly S, Garrouste-Orgeas M, Kentish-Barnes N, Duranteau J, Thuong M, Joseph L, Renault A, Lesieur O, Larbi AGS, Viquesnel G, Zuber B, Marque S, Kandelman S, Pichon N, Floccard B, Galon M, Chevret S, Kentish-Barnes N, Seegers V, Legriel S, Jaber S, Lefrant JY, Reuter D, Guisset O, Cracco C, Seguin A, Durand-Gasselin J, Thirion M, Cohen-Solal Z, Foulgoc H, Rogier J, Delobbe E, Schortgen F, Asfar P, Julie BH, Grimaldi D, Fabien G, Anguel N, Sigismond L, Matthieu HL, Gonzalez F, François L, Guitton C, Schenck M, Jean-Marc D, Radermacher P, Kentish-Barnes N, Makunza JN, Nathalie MK, Pierre A, Adolphe KM, Mahieu R, Reydel T, Jamet A, Chudeau N, Huntzinger J, Grange S, Courte A, Lemarie J, Gibot S, Champey J, Dellamonica J, Du Cheyron D, Contou D, Tadié JM, Cour M, Beduneau G, Marchalot A, Guérin L, Jochmans S, Terzi N, Preau S, Brun-Buisson C, Dessap AM, Vedrenne-Cloquet M, Breinig S, Jung C, Brussieux M, Marcoux MO, Durrmeyer X, Blondé R, Angoulvant F, Grasset J, Naudin J, Dauger S, Remy S, Kolev-Descamp K, Demaret J, Monneret G, Javouhey E, Chomton M, Sauthier M, Vallieres E, Jouvet P, Geslain G, Guellec I, Rambaud J, Schmidt M, Schellongowski P, Dorget A, Patroniti N, Taccone FS, Miranda DR, Reuter J, Prodanovic H, Pierrot M, Balik M, Park S, Guérin C, Papazian L, Jean R, Ayzac L, Loundou A, Forel JM, Mezidi M, Aublanc M, Perinel-Ragey S, Lissonde F, Louf-Durier A, Tapponnier R, Yonis H, Coudroy R, Frat JP, Boissier F, Thille AW, Richard F, Le Gullou-Guillemette H, Fahri J, Kouatchet A, Bodet-Contentin L, Garot D, Le Pennec D, Vecellio L, Tavernier E, Dequin PF, Messika J, Martin Y, Maquigneau N, Puechberty C, Stoclin A, Villard S, Dechanet A, De Jong A, Monnin M, Girard M, Chanques G, Molinari N, Decavèle M, Campion S, Ainsouya R, Niérat MC, Raux M, Similowski T, Demoule A, Razazi K, Tchir M, May F, Carteaux G, Pauline RB, Marc A, Bedos JP, Mehrsa K, Mauger-Briche C, Mijon F, Trouiller P, Sztrymf B, Cretallaz P, Mermillod-Blondin R, Savary D, Sedghiani I, Doghri H, Jendoubi A, Hamdi D, Cherif MA, Hechmi YZE, Zouheir J, Persico N, Maltese F, Ferrigno C, Bablon A, Marmillot C, Roch A, Sedghiani I, Papin G, Gainnier M, Argaud L, Christophe A, Souweine B, Goldgran-Toledano D, Marcotte G, Dumenil AS, Carole S, Cecchini J, Tuffet S, Fartoukh M, Roux D, Thyrault M, Armand MD, Chauveau S, Wesner N, Monnier-Cholley L, Bigé N, Ait-Oufella H, Guidet B, Dubée V, Labroca P, Lemarié J, Chiesa G, Laroyenne I, Borrini L, Klotz R, Sy QP, Cristina MC, Paysant J, Fillâtre P, Gacouin A, Revest M, Tattevin P, Flecher E, Le Tulzo Y, Jamme M, Daviaud F, Marin N, Thy M, Duceau B, Ardisson F, Sandrine V, Venot M, Schlemmer B, Zafrani L, Pons S, Styfalova L, Bouadma L, Radjou A, Lebut J, Mourvillier B, Dorent R, Dilly MP, Nataf P, Wolff M, Le Gall A, Bourcier S, Tandjaoui-Lambiotte Y, Das V, Alves M, Bigé N, Kamilia C, Rania A, Baccouch N, Turki O, Ben HC, Bahloul M, Bouaziz M, Dupuis C, Perozziello A, Letheulle J, Valette M, Herrmann-Storck C, Crosby L, Elkoun K, Madeux B, Martino F, Migueres H, Piednoir P, Posch M, Thiery G, Huynh-Ky MT, Bouchard PA, Sarrazin JF, Lellouche F, Nay MA, Lortat-Jacob B, Rozec B, Colnot M, Belin N, Barrot L, Navellou JC, Patry C, Chaignat C, Claveau M, Claude F, Aubron C, Mcquilten Z, Bailey M, Board J, Buhr H, Cartwright B, Dennis M, Forrest P, Hodgson C, Mcilroy D, Murphy D, Murray L, Pellegrino V, Pilcher D, Sheldrake J, Tran H, Vallance S, Cooper J, Bombled C, Vidal C, Margetis D, Amour J, Coart D, Dubois J, Van Herpe T, Mesotten D, Bailly S, Lucet J, Lepape A, L’hériteau F, Aupée M, Bervas C, Boussat S, Berger-Carbonne A, Machut A, Savey A, Tudesq JJ, Valade S, Galicier L, De Bazelaire C, Munoz-Bongrand N, Mignard X, Biard L, Mokart D, Nyunga M, Bruneel F, Rabbat A, Perez P, Meert AP, Benoit D, Mariotte E, Ehooman F, Hamidfar-Roy R, Hourmant Y, Mailloux A, Beurton A, Teboul JL, Girroto V, Laura G, Richard C, Monnet X, Dubée V, Merdji H, Dang J, Preda G, Baudel JL, Desnos C, Zeitouni M, Belaroussi I, Parrot A, Blayau C, Fulgencio JP, Quesnel C, Labbe V, De Chambrun MP, Beloncle F, Merceron S, Fedun Y, Lecomte B, Devaquet J, Puidupin M, Verdière B, Amoura Z, Vuillard C, Xavier J, Bourlier D, David A, Caroline S, David M, Gerald S, Olivier S, Humbert M, Laurent S, Dujardin O, Bouglé A, Ait HN, Salem JE, El-Helali N, Coppere Z, Gibelin A, Taconet C, Djibre M, Maamar A, Colobert E, Fillatre P, Uhel F, Camus C, Moraly J, Dahoumane R, Maury E, Tan BK, Emmanuel V, Pauline M, Laurence P, Philippe P, Zahar JR, Catherine H, Christian P, Karim AB, Mounia H, Laura T, Rasoldier VH, Mager G, Eraldi JP, Gelinotte S, Bougerol F, Dehay J, Rigaud JP, Declercq PL, Michel J, Aissa N, Henard S, Guerci P, Latar I, Levy B, Girerd N, Kimmoun A, Abdallah SB, Nakaa S, Hraiech K, Braiek DB, Adhieb A, M’ghirbi A, Ousji A, Hammouda Z, Abroug F, Sellami W, Hajjej Z, Samoud W, Labbene I, Ferjani M, Medhioub FK, Allela R, Algia NB, Cherif S, Attia D, Herinjatovo A, Francois XL, Bouhouri MA, Slaoui MT, Soufi A, Khaleq K, Hamoudi D, Nsiri A, Harrar R, Maury E, Goursaud S, Gauberti M, Labeyrie PE, Gaberel T, Agin V, Maubert E, Vivien D, Gakuba C, Armel A, Abdou R, Kalouch S, Yaqini K, Chlilek A, Sellami W, Yedder SB, Tonnelier A, Hervé F, Halley G, Frances JL, Moriconi M, Saoli M, Garnero A, Demory D, Arnal JM, Canoville B, Daubin C, Brunet J, Ghezala HB, Snouda S, Ben CI, Kaddour M, Ouanes I, Marzouk M, Haniez F, Jaillet H, Maas H, Andrivet P, Darné C, Viau F, Ghezala HB, Ouanes I, Dangers L, Montlahuc C, Perbet S, Ouanes I, Hamouda Z, Nakee S, Ouanes-Besbes L, Meddeb K, Khedher A, Sma N, Ayachi J, Khelfa M, Fraj N, Lakhal HB, Hammed H, Boukadida R, Hafsa H, Chouchene I, Boussarsar M, Ben BD, Ouanes-Besbes L, Benatti K, Dafir A, Aissaoui W, Elallame W, Haddad W, Cherkab R, Elkettani C, Barrou L, Hamou ZA, Repessé X, Charron C, Aubry A, Paternot A, Maizel J, Slama M, Vieillard-Baron A, Trifi A, Abdellatif S, Fatnassi M, Daly F, Nasri R, Ismail KB, Lakhal SB, Bazalgette F, Daurat A, Roger C, Muller L, Doyen D, Plattier R, Robert A, Hyvernat H, Bernardin G, Jozwiak M, Gimenez J, Mercado P, Depret F, Tilouch N, Mater H, Habiba BSA, Jaoued O, Gharbi R, Hassen MF, Elatrous S, Pasquier P, Vuillemin Q, Schaal JV, Martinez T, Duron S, Trousselard M, Schwartzbrod PE, Baugnon T, Dupic L, Gout CD, De Saint Blanquat L, Séguret S, Le Ficher G, Orliaguet G, Hubert P, Bigé N, Leblanc G, Briand R, Brousse L, Brunet V, Chatelain L, Prat D, Jacobs F, Demars N, Hamzaoui O, Moneger G, Sztrymf B, Duburcq-Gury E, Satre-Buisson L, Duburcq T, Poissy J, Robriquet L, Jourdain M, Sécheresse T, Miquet M, Simond A, Usseglio P, Hamdaoui Y, Boussarsar M, Desailly V, Brun P, Iglesias P, Huet J, Masseran C, Claudon A, Ebeyer C, Truong T, Tesnière A, Mignon A, Gaudry S, Resiere D, Valentino R, Fabre J, Roze B, Ferge JL, Charbatier C, Marie S, Scholsser M, Aitsatou S, Raad M, Cabie A, Mehdaoui H, Cousin C, Rousseau C, Llitjos JF, Alby-Laurent F, Toubiana J, Belaidouni N, Cherruault M, Tamburini J, Bouscary D, Fert S, Delile E, Besnier E, Coquerel D, Nevière R, Richard V, Tamion F, Wei C, Louis H, Margaux S, Eliane A, Sophie O, Kimmoun A, Riad Z, Coroir M, Rémy B, Camille B, Joffre J, Aegerter P, Ilic D, Ginet M, Pignard C, Nguyen P, Mourey G, Samain E, Pili-Floury S, Jouffroy R, Nicolas C, Alvarez JC, Tomasso M, Philippe P, Raphalen JH, Frédéric JB, Vivien B, Pierre C, Baud F, Fredj H, Blel Y, Brahmi N, Ghezala HB, Hanak AS, Malissin I, Poupon J, Risede P, Chevillard L, Megarbane B, Barghouth M, M’rad A, Hmida MB, Thabet H, Liang H, Callebert J, Lagard C, Megarbane B, Habacha S, Chatbri B, Camillerapp C, Labat L, Soichot M, Garçon P, Goury A, Kerdjana L, Voicu S, Deye N, Megarbane B, Armel A, Anas B, Othman M, Moumine S, Kalouch S, Yakini KK, Chlilek A, Hajji A, Louati A, Khaldi A, Borgi A, Ghali N, Bouziri A, Menif K, Ben JN, Armel A, Brochon J, Dumitrescu M, Thévenot S, Saulnier JP, Husseini K, Laland C, Cremniter J, Bousseau A, Castel O, Brémaud-Csizmadia C, Diss M, Portefaix A, Berthiller J, Gillet Y, Aoul NT, Douah A, Addou Z, Youbi H, Moussati M, Belhabiche K, Mir S, Abada S, Amel Z, Aouffen N, Bouzit Z, Grati AH, Dhonneur GF, Boussarsar M, Lau N, Mezhari I, Roucaud N, Le Meur M, Paulet R, Coudray JM, Ghomari WI, Boumlik R, Peigne V, Daban JL, Boutonnet M, Lenoir B, Yassine H, Mohamed CC, Khalid A, Ihssan M, Said E, Said S, Jazia AB, Fatima J, Wafa S, Maha B, Khaoula BA, Sami T, Abdallah Taeib B, Medhioub FK, Rollet-Cohen V, Sachs P, Merchaoui Z, Renolleau S, Oualha M, Eloi M, Jean S, Demoulin M, Valentin C, Guilbert J, Walti H, Carbajal R, Leger PL, Karaca-Altintas Y, Botte A, Labreuche J, Drumez E, Devos P, Bour F, Leclerc F, Ahmed A, khaled M, Louati A, Aida B, Ammar K, Narjess G, Ahmed H, Asma B, Jaballah NB, Leger PL, Pansiot J, Besson V, Palmier B, Baud O, Cauli B, Charriaut-Marlangue C, Mansuy A, Michel F, Le Bel S, Boubnova J, Ughetto F, Ovaert C, Fouilloux V, Paut O, Jacquet-Lagrèze M, Tiebergien N, Hanna N, Evain JN, Baudin F, Courtil-Teyssedre S, Bompard D, Lilot M, Chardonal L, Fellahi JL, Claverie C, Pouessel G, Dorkenoo A, Renaudin JM, Eb M, Deschildre A, Leteurtre S, Yassine H, Kamal B, Adil O, Ouafa A, Mouhamed M, Rachid C, Lahoucine B, Dachraoui F, Nakkaa S, Zaineb H, Mlika D. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress. Ann Intensive Care 2017. [PMCID: PMC5225387 DOI: 10.1186/s13613-016-0223-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
22
|
Obeid S, Ceroi A, Mourey G, Saas P, Elie-Caille C, Boireau W. Development of a NanoBioAnalytical platform for "on-chip" qualification and quantification of platelet-derived microparticles. Biosens Bioelectron 2016; 93:250-259. [PMID: 27597127 DOI: 10.1016/j.bios.2016.08.100] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Revised: 08/14/2016] [Accepted: 08/28/2016] [Indexed: 11/18/2022]
Abstract
Blood microparticles (MPs) are small membrane vesicles (50-1000nm), derived from different cell types. They are known to play important roles in various biological processes and also recognized as potential biomarkers of various health disorders. Different methods are currently used for the detection and characterization of MPs, but none of these methods is capable to quantify and qualify total MPs at the same time, hence, there is a need to develop a new approach for simultaneous detection, characterization and quantification of microparticles. Here we show the potential of surface plasmon resonance (SPR) method coupled to atomic force microscopy (AFM) to quantify and qualify platelet-derived microparticles (PMPs), on the whole nano-to micro-meter scale. The different subpopulations of microparticles could be determined via their capture onto the surface using specific ligands. In order to verify the correlation between the capture level and the microparticles concentration in solution, two calibration standards were used: Virus-Like Particles (VLPs) and synthetic beads with a mean diameter of 53nm and 920nm respectively. The AFM analysis of the biochip surface allowed metrological analysis of captured PMPs and revealed that more than 95% of PMPs were smaller than 300nm. Our results suggest that our NanoBioAnalytical platform, combining SPR and AFM, is a suitable method for a sensitive, reproducible, label-free characterization and quantification of MPs over a wide concentration range (≈107 to 1012 particles/mL; with a limit of detection (LOD) in the lowest ng/µL range) which matches with their typical concentrations in blood.
Collapse
Affiliation(s)
- Sameh Obeid
- FEMTO-ST Institute, UBFC, CNRS, ENSMM, UTBM, 15B Avenue des Montboucons, 25030 Besançon, France
| | - Adam Ceroi
- INSERM U1098, EFS Bourgogne Franche-Comté, UBFC, 25000 Besançon, France
| | - Guillaume Mourey
- INSERM U1098, EFS Bourgogne Franche-Comté, UBFC, 25000 Besançon, France
| | - Philippe Saas
- INSERM U1098, EFS Bourgogne Franche-Comté, UBFC, 25000 Besançon, France
| | - Celine Elie-Caille
- FEMTO-ST Institute, UBFC, CNRS, ENSMM, UTBM, 15B Avenue des Montboucons, 25030 Besançon, France
| | - Wilfrid Boireau
- FEMTO-ST Institute, UBFC, CNRS, ENSMM, UTBM, 15B Avenue des Montboucons, 25030 Besançon, France.
| |
Collapse
|
23
|
Ceroi A, Delettre FA, Marotel C, Gauthier T, Asgarova A, Biichlé S, Duperrier A, Mourey G, Perruche S, Lagrost L, Masson D, Saas P. The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation. Haematologica 2015; 101:e72-6. [PMID: 26635040 DOI: 10.3324/haematol.2015.135459] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Affiliation(s)
- Adam Ceroi
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon
| | - Fanny Angelot Delettre
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon
| | - Charline Marotel
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon
| | - Thierry Gauthier
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon
| | - Afag Asgarova
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon
| | - Sabéha Biichlé
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon
| | - Anne Duperrier
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon
| | - Guillaume Mourey
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon
| | - Sylvain Perruche
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon
| | - Laurent Lagrost
- LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon INSERM, U866, Dijon Université Bourgogne Franche-Comté, UMR866, Dijon CHRU Dijon
| | - David Masson
- LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon INSERM, U866, Dijon Université Bourgogne Franche-Comté, UMR866, Dijon CHRU Dijon
| | - Philippe Saas
- INSERM, UMR1098, Besançon EFS Bourgogne Franche-Comté, UMR1098, Besançon Université Bourgogne Franche-Comté, UMR1098, Besançon LabEX LipSTIC, ANR-11-LABX-0021, Besançon/Dijon CHRU Besançon, INSERM CIC1431, FHU INCREASE, France
| |
Collapse
|
24
|
Isola H, Dupuis A, Naegelen C, Marpaux N, Mourey G, Ravanat C, Laforet M, Gachet C, Morel P. Traitement photochimique d’un mélange de plasmas issus de sang total et congélation dans un délai de 18 à 19heures après le prélèvement. Transfus Clin Biol 2015. [DOI: 10.1016/j.tracli.2015.06.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
25
|
Ravanat C, Dupuis A, Marpaux N, Naegelen C, Mourey G, Isola H, Laforêt M, Morel P, Gachet C. Test de génération de thrombine après traitement photochimique et conservation de plasma dérivé de sang total. Transfus Clin Biol 2015. [DOI: 10.1016/j.tracli.2015.06.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
26
|
Courdier C, Gil H, Mourey G, Riethmuller D, Humbert S, Magy-Bertrand N. Comparaison des grossesses chez les femmes porteuses d’anticorps antiphospholipides « non pathogènes » à celles chez les femmes porteuses d’anticorps antiphospholipides « pathogènes ». Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
de Maistre E, Volot F, Mourey G, Aho LS, Ternisien C, Briquel ME, Bertrand MA, Tardy B, Frotscher B, Nguyen P, Dumont L, Vandroux D, Hézard N, Trossaërt M. Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance. Thromb Haemost 2014; 112:825-30. [PMID: 25103956 DOI: 10.1160/th14-02-0108] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Accepted: 04/30/2014] [Indexed: 11/05/2022]
Abstract
The ristocetin cofactor activity assay (VWF:RCo) is the reference method for assessing von Willebrand factor (VWF) activity but remains difficult to perform, and the coefficient of variation of the method is high (about 20-30%). This study evaluated and compared the performance for measuring the VWF activity of two newly commercialised assays [VWF:Ac Innovance (VWF:Ac) and VWF:RCo Acustar (VWF:RCo Acu)] with the reference VWF:RCo aggregation in 123 pathological plasma samples. The correlation and concordance between both new tests (VWF:RCo-Acu and VWF:Ac) and the reference VWF:RCo were good. The results of the VWF activity to VWF antigen ratio were also comparable whatever the method for the classification of VWF deficiency in all patients. Our results showed that both new tests could replace the "gold standard" VWF:RCo in aggregometry with several benefits: they are fully automated, easier and faster to perform, better adapted to emergency situations if necessary.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Marc Trossaërt
- Dr. Marc Trossaërt, Centre Régional de Traitement de l'Hémophilie, 1 Place Alexis RICORDEAU, Centre Hospitalier Universitaire, 44093 Nantes Cedex 1, France, Tel.: +33 2 40 08 74 68, Fax: +33 2 40 08 42 59, E-mail:
| |
Collapse
|
28
|
Mourey G, Tachon G, Pellequer JL, Zawadzki C, Trossaërt M, Bertrand MA, Schved JF, Giansily-Blaizot M. A Haut-Doubs FVII variant depending on species-derived-thromboplastin reagent (F7:p.Arg337His). Haemophilia 2014; 20:e347-9. [DOI: 10.1111/hae.12455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/26/2014] [Indexed: 11/27/2022]
Affiliation(s)
- G. Mourey
- Laboratoire d'hémostase; Etablissement Français du Sang; Besançon France
| | - G. Tachon
- Département d'hématologie biologique; CHU de Montpellier; Hôpital Saint Eloi; Montpellier France
| | - J.-L. Pellequer
- CEA, iBEB; Service de Biochimie et Toxicologie Nucléaire; Bagnols sur Cèze France
| | - C. Zawadzki
- Laboratoire d'Hématologie; Centre de Biologie et Pathologie EA-2693; Centre Hospitalier Régional et Universitaire; Lille France
| | - M. Trossaërt
- Centre Régional de Traitement de l'Hémophilie; Laboratoire hématologie; CHU Hôtel-Dieu; Nantes France
| | - M.-A. Bertrand
- Centre Régional de Traitement de l'Hémophilie; Service d'hématologie CHU Besançon; Besançon France
| | - J.-F. Schved
- Département d'hématologie biologique; CHU de Montpellier; Hôpital Saint Eloi; Montpellier France
| | - M. Giansily-Blaizot
- Département d'hématologie biologique; CHU de Montpellier; Hôpital Saint Eloi; Montpellier France
| |
Collapse
|
29
|
Laresche C, Pelletier F, Garnache-Ottou F, Lihoreau T, Biichlé S, Mourey G, Saas P, Humbert P, Seilles E, Aubin F. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol 2014; 134:176-182. [PMID: 23812302 DOI: 10.1038/jid.2013.288] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2012] [Revised: 01/19/2013] [Accepted: 02/06/2013] [Indexed: 12/21/2022]
Abstract
Microparticles (MPs) are known to be increased in various malignancies and are involved in tumor invasion, angiogenesis, coagulation, and metastasis. We investigated the plasma levels of annexin-V MPs (AV(+)MPs), platelet-derived MPs (PMPs), and endothelial-derived MPs (EMPs) in patients with melanoma (n=129) and in healthy controls (n=49). A functional coagulation test STA Procoag-PPL measuring the clotting time was performed on samples containing MPs to evaluate their procoagulant potential. The plasma levels of PMPs, EMPs, and AV(+)MPs were significantly higher, and the clotting time-PPL was significantly lower in melanoma patients than in healthy controls. The plasma levels of PMPs, EMPs, and AV(+)MPs were higher in stage IV than in the other stages of melanoma, but with no significant difference. In addition, we observed an inverse correlation between PMPs, AV(+)MPs, and clotting times. Our data suggest that MPs are involved in the progression of melanoma and may be associated to melanoma-associated thrombogenesis.
Collapse
Affiliation(s)
- Claire Laresche
- Service de Dermatologie, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France
| | - Fabien Pelletier
- Service de Dermatologie, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France; Université de Franche Comté, INSERM UMR 1098, SFR FED4234, Besançon, France.
| | - Francine Garnache-Ottou
- Université de Franche Comté, INSERM UMR 1098, SFR FED4234, Besançon, France; Etablissement Français du Sang Bourgogne Franche Comté, Besançon, France
| | - Thomas Lihoreau
- Service de Dermatologie, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France
| | - Sabeha Biichlé
- Université de Franche Comté, INSERM UMR 1098, SFR FED4234, Besançon, France; Etablissement Français du Sang Bourgogne Franche Comté, Besançon, France
| | - Guillaume Mourey
- Université de Franche Comté, INSERM UMR 1098, SFR FED4234, Besançon, France; Etablissement Français du Sang Bourgogne Franche Comté, Besançon, France
| | - Philippe Saas
- Université de Franche Comté, INSERM UMR 1098, SFR FED4234, Besançon, France; Etablissement Français du Sang Bourgogne Franche Comté, Besançon, France
| | - Philippe Humbert
- Service de Dermatologie, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France; Université de Franche Comté, INSERM UMR 1098, SFR FED4234, Besançon, France
| | - Estelle Seilles
- Université de Franche Comté, INSERM UMR 1098, SFR FED4234, Besançon, France; Etablissement Français du Sang Bourgogne Franche Comté, Besançon, France
| | - François Aubin
- Service de Dermatologie, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France; Université de Franche Comté, EA3181, SFR FED4234, Besançon, France
| |
Collapse
|
30
|
Stagnara J, Garnache Ottou F, Angelot F, Mourey G, Seilles E, Biichlé S, Saas P, Racadot E. Correlation between platelet-derived microparticle enumeration by flow cytometry and phospholipid-dependent procoagulant activity in microparticles: the centrifugation step matters! Thromb Haemost 2012; 107:1185-7. [PMID: 22476436 DOI: 10.1160/th11-07-0509] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2011] [Accepted: 02/24/2012] [Indexed: 11/05/2022]
|